Nile Therapeutics announced that the FDA has granted fast track designation to cenderitide to reduce cardiovascular mortality and re-hospitalization in the post-acute period in patients with acutely decompensated heart failure (ADHF). Cenderitide is being developed as an outpatient therapy to be delivered to ADHF patients continuously for up to 90 days after hospital discharge.  

Cenderitide is a natriuretic peptide receptor agonist that acts on multiple disease processes that play a role in the negative outcomes associated with heart failure. It is being investigated for its effects in reducing cardiac pressure, improving diuresis, preservation of renal function, and blood pressure reduction.

For more information call (650) 458-2670 or visit www.nilethera.com.